同写意论坛第93期 | 2019中美医疗投资论坛和路演

会议时间：

2019年6月14日

会议地点：

美国

标签：

行业会议

热度：

34226

现场丨同写意携手SAPA在美主办2019中美医疗投资论坛和路演活动

部分专家合影

同写意在国内辛勤耕耘15载，举办药品研发创新活动超过90期，2019年6月14日，同写意走出国门，携手SAPA，在美国新泽西/纽约举办一场中美医疗投资论坛和路演活动，这也是同写意第93期活动。对于同写意，这是一个里程碑的活动。

本次活动四位co-chair

从左至右：薛军、王进、陈晓东、程增江

SAPA医疗投资论坛和路演年度活动由SAPA总部主办，2018年首届活动为期一天。今年的活动增加至两天，第一天（14日）的活动由同写意Host，突出中国投资创新元素，邀请分享投资等中国本土的资深投资人，介绍中国医药产业的新趋势和新未来，并组织多家海归生物医药创新公司的创始人，分享国内创业、融资与发展的心得体会，让美国投资界更好地了解中国生物医药前所未有的发展机遇，促进中国生物医药界更好地与美国资源融合发展。

同写意与SAPA的携手，带来了一场真正意义上的中美医疗投资论坛。

欢迎致辞

▼

陈晓东博士

投资路演论坛共同主席、美中药协常务副会长

SAPA这个活动宗旨的就是promote business cooperation in healthcare and pharmaceutical。这次论坛也是为SAPA会员创业创建一个平台，帮助了解国内外的投资趋势，解决创新途中遇到的问题，让Brightest mind meet smartest money. 陈博士讲到与程博士早在2016就在华盛顿就结识，经常在新闻中看到同写意在国内组织高质量的会议，这次终于能够与同写意携手一起写意北美，非常期待。他开玩笑讲到，之前在BMS的一些老同事，去过几次同写意做演讲以后就海归做了公司高管，说明同写意的平台非常高效。

▼

刘晚生博士

SAPA候任会长

On behalf of SAPA, I welcome you all and thank you for attending the 2019 SAPA Healthcare Investment Forum by taking time out of your busy schedule on a beautiful work day like this. Our special welcome goes to our friends coming from China, especially our event collaborator Tong Xie Yi and sponsor Share Capital. Thank them for putting today’s program together. It’s our privilege and honor to collaborate with a distinguished organization such as Tong Xie Yi. Next I’m going to briefly introduce SAPA to you, especially those who are attending the SAPA event for the first time……Finally, let’s give our warmest welcome to Dr. Zengjiang Cheng, the co-Chair of the event and the Founder of Tong Xie Yi, who will give some opening remarks.

▼

程增江博士

同写意论坛发起人、科贝源（北京）生物医药科技公司董事长

I have participated in SAPA forums twice as a speaker and made many friends in SAPA.

SAPA is one of the most active Chinese professional associations in the US, and has already become a broad platform for scientific and technical discussion, talent exchange, and training for the colleagues in the pharmaceutical industry from the US and China.

Tongxieyi has been considered as an important platform sharing values and a spirit home for the pharmaceutical elites. It has become one of the most important recourses of new ideas for new drug development in China.

It's a great honor for me to join hands with SAPA in hosting the SAPA Health Care Investment Forum and Roadshow in 2019.

上篇·Morning Session

生物医药产业创新发展的机遇与红利

Incentivizing Innovation in Biomedical and Pharma Industry

▼

【主持】

杜新博士

杭州阿诺监管事务和质量高级副总裁

SAPA和同写意是我非常喜欢的在美国和中国的活动组织，这次双方携手共同举办中美投资论坛我特别高兴。

▼

杜涛博士

分享投资医疗基金合伙人

中国医药产业的新趋势和新未来

New Challenges and Opportunities in Chinese Pharmaceutical Industry

Pharmaceutical industry is an immortal industry
Demand for quality medicine is universal
Development of Chinese pharmaceutical industry will bring huge opportunities to both global and Chinese investors
Technology capitalization will accelerate the development of Chinese pharmaceutical industry

▼

赵孝斌博士

前美FDA仿制药办公室（OGD）高级审评员、浙江海昶生物医药技术有限公司创始人

分享进取，求真务实

Shared Ambition, Real Solution — Entrepreneurial Stories of HAICHANG BioTech

▼

黄反之

分享投资医疗基金主管合伙人

精准医疗对医疗产业的重构

Precision Medicine: Reshaping the Future of Healthcare Industry

▼

谢开

分享投资医疗基金合伙人

中国医改进程及投资趋势

China’s Healthcare Reform Progress and Investment Climate

The healthcare industry shows a relatively strong power of growth despite of the economic fluctuation.

China’s regulatory policies and capital markets are giving green lights to innovative drugs and biotechnologies, bringing companies in this field into the spotlight.

The ongoing China’s healthcare reform is in a sense trying to “disassemble” large public hospitals, by allowing all production factors to flow freely in the market, so as to build a multi-layered medical service system.

Almighty big hospitals → Network of various medical service providers. Strategies of R&D, product positioning, marketing and distributing need to adapt accordingly.

▼

Panel Discussion: Incentivising Innovation in Biomedical and Pharma Industry

【主持】谢开

【嘉宾】杜涛、黄反之、赵孝斌、王进

下篇·Afternoon Session

Pharmaceutical Innovation and Entrepreneurship

from Returned Overseas Elites

【主持】谢开：分享投资医疗基金董事总经理

▼

Brad Loncar

CEO , Loncar Investments

Biotech Market Dynamics in China

Generic drugs have gone from being virtually the only business in China to the worst business in China overnight. This is a positive for innovators.

▼